B‐Type Natriuretic Peptide as a Marker of Subclinical Heart Disease in a High‐Burden Emergency Department Population With Sustained Asymptomatic Hypertension
Authors:
- Kimberly SouffrontKSKimberly Souffront
- Bret P. NelsonBNBret P. Nelson
- Hans Reyes GarayHGHans Reyes Garay
- Claire ShubeckCSClaire Shubeck
- Lauren GordonLGLauren Gordon
- George T. LooGLGeorge T. Loo
- Aleksandra DegtyarADAleksandra Degtyar
- Marcee WilderMWMarcee Wilder
- Bernice ColemanBCBernice Coleman
- Lynne D. RichardsonLRLynne D. Richardson
Open Access
- 1 January 2025
- journal article
- Published by Wiley in International Journal of Hypertension
- Vol. 2025 (1)
Abstract
B‐Type natriuretic peptide (BNP) levels below contemporary thresholds for diagnosing congestive heart failure are associated with subclinical heart disease (SHD) and adverse cardiovascular outcomes in community patients with uncontrolled asymptomatic hypertension. This study aimed to determine the accuracy of BNP for detecting SHD in emergency patients with sustained asymptomatic hypertension, where SHD is universally prevalent. Conducted at two urban academic emergency departments within a seven‐hospital healthcare organization, this proof‐of‐concept study included adults with sustained asymptomatic hypertension (initial BP ≥ 160/100 mmHg and second BP ≥ 140/90 mmHg), excluding those with congestive heart failure, renal insufficiency, atrial fibrillation, pregnancy, incarceration, cognitive impairment, and symptomatic hypertension. Enrolled patients underwent bedside echocardiograms, BNP lab tests, and electrocardiograms. All 78 patients (100%) had SHD. The cohort was predominantly female (55.1%), middle‐aged (mean age: 52 ± 15.2 years), with Class I obesity (mean BMI: 32.3 ± 8.3) and a high prevalence of hypertension history (55.1%). Common findings included left ventricular hypertrophy (86%), diastolic dysfunction (70.5%), and left ventricular systolic dysfunction (12.2%). The BNP lab test accurately detected SHD in nearly 60% of patients, with a Type II error rate of approximately 40%. In this proof‐of‐concept study, BNP underperformed in a cohort with universally present SHD, suggesting that sole reliance on BNP may lead to missed opportunities for early intervention.Keywords
Funding Information
- Gordon and Betty Moore Foundation (GBMF9048)
- National Institutes of Health (5T32HL160513)
- National Institutes of Health (5U54CA267776)
This publication has 34 references indexed in Scilit:
- A Scoping Review of Asymptomatic Hypertension: Definitions, Diagnosis, and Management in the Emergency DepartmentCurrent Hypertension Reports, 2025
- Prevalence of undiagnosed stage B heart failure among emergency department patientsThe American Journal of Emergency Medicine, 2024
- Racial and ethnic differences in circulating N-terminal pro-brain-type natriuretic peptide (NT-proBNP) in US adultsAmerican Journal of Preventive Cardiology, 2023
- Emergency Nursing Policy and Hypertension Awareness: an Integrative Review of the LiteratureCurrent Hypertension Reports, 2019
- New Approaches to Evaluating and Monitoring Blood PressureCurrent Hypertension Reports, 2016
- Subclinical Hypertensive Heart Disease in Black Patients With Elevated Blood Pressure in an Inner-City Emergency DepartmentAnnals of Emergency Medicine, 2012
- Left ventricular dysfunction screening in hypertensive patients with N-terminal pro–B-type natriuretic peptide and electrocardiogramThe American Journal of Emergency Medicine, 2012
- The paradox of low BNP levels in obesityHeart Failure Reviews, 2011
- The Role of N-terminal PRO-Brain Natriuretic Peptide and Echocardiography for Screening Asymptomatic Left Ventricular Dysfunction in a Population at High Risk for Heart Failure. The PROBE-HF StudyJournal of Cardiac Failure, 2009
- Increased Blood Pressure in the Emergency Department: Pain, Anxiety, or Undiagnosed Hypertension?Annals of Emergency Medicine, 2008